Titan shareholders approve business combination with Black Titan; 730,383 votes for, 1,860 against

TITAN PHARMACEUTICALS INC

At special meeting on August 26, 2025, stockholders voted 730,383 for, 1,860 against, and 1,902 abstentions on Business Combination Proposal.
Nasdaq Proposal approved 730,049 for, 2,127 against, 1,969 abstentions to authorize issuance of Black Titan ordinary shares.
Adjournment Proposal approved 729,943 for, 3,808 against, 394 abstentions.
No broker non-votes were reported; completion of merger still subject to other conditions including Nasdaq listing approval.

item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.